Clinical epidemiology and molecular analysis of extended-spectrum-β-lactamase-producing Escherichia coli in Nepal: Characteristics of sequence types 131 and 648

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3424-3432

  Sherchan, Jatan Bahadur ^a   Hayakawa, Kayoko ^a,b   Miyoshi Akiyama, Tohru ^b   Ohmagari, Norio ^b   Kirikae, Teruo ^b   Nagamatsu, Maki ^b   Tojo, Masayoshi ^b   Ohara, Hiroshi ^b   Sherchand, Jeevan B ^c   Tandukar, Sarmila ^c  

^a KATHMANDU UNIVERSITY SCHOOL OF MEDICAL SCIENCES   (Nepal)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c TRIBHUVAN UNIVERSITY TEACHING HOSPITAL   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MINOCYCLINE; O ANTIGEN; UNCLASSIFIED DRUG; BETA LACTAMASE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; GENE SEQUENCE; GENETIC RESISTANCE; GENOTYPE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NEPAL; NONHUMAN; PRIORITY JOURNAL; ADOLESCENT; AGED; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PATHOGENICITY; VIRULENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; NEPAL; VIRULENCE; YOUNG ADULT;

EID: 84929603597     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00270-15     Document Type: Article

References (32)

1. National Nosocomial Infections Surveillance System. 1996. Data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 24:380-388.
2. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120. http://dx.doi.org/10.1093/cid/ciq257.
3. Klein JO, Feigin RD, McCracken GH, Jr. 1986. Report of the Task Force on Diagnosis and Management of Meningitis. Pediatrics 78:959-982.
4. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
5. Johnson JR, Urban C, Weissman SJ, Jorgensen JH, Lewis JS, II, Hansen G, Edelstein PH, Robicsek A, Cleary T, Adachi J, Paterson D, Quinn J, Hanson ND, Johnston BD, Clabots C, Kuskowski MA, AMERECUS Investigators. 2012. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-beta-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 56:2364-2370. http://dx.doi.org/10.1128/AAC.05824-11.
6. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66:1-14. http://dx.doi.org/10.1093/jac/dkq415.
7. Reardon S. 2014. Antibiotic resistance sweeping developing world. Nature 509:141-142. http://dx.doi.org/10.1038/509141a.
8. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. Approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Afridi FI, Farooqi BJ. 2012. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum beta-lactamase producing Enterobacteriaceae in urinary isolates. J Coll Physicians Surgeons Pakistan 22:358-362.
10. Kresken M, Pfeifer Y, Hafner D, Wresch R, Korber-Irrgang B, Working Party 'Antimicrobial Resistance' of the Paul-Ehrlich-Society for Chemotherapy. 2014. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum beta-lactamases and the role of fosfomycin. Int J Antimicrob Agents 44:295-300. http://dx.doi.org/10.1016/j.ijantimicag.2014.05.020.
11. Yang Q, Zhang H, Cheng J, Xu Z, Xu Y, Cao B, Kong H, Ni Y, Yu Y, Sun Z, Hu B, Huang W, Wang Y, Wu A, Feng X, Liao K, Shen D, Hu Z, Chu Y, Lu J, Su J, Gui B, Duan Q, Zhang S, Shao H. 31 December 2014. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum beta-lactamases in China. Int J Antimicrob Agents http://dx.doi.org/10.1016/j.ijantimicag.2014.11.012.
12. Grimm H. 1991. Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef. Infection 19(Suppl 5):S258-S263. http://dx.doi.org/10.1007/BF01645537.
13. Jones RN, Barry AL, Packer RR, Gregory WW, Thornsberry C. 1987. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination. J Clin Microbiol 25:1725-1729.
14. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Approved standard M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66:4555-4558. http://dx.doi.org/10.1128/AEM.66.10.4555-4558.2000.
16. Banerjee R, Robicsek A, Kuskowski MA, Porter S, Johnston BD, Sokurenko E, Tchesnokova V, Price LB, Johnson JR. 2013. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and -negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob Agents Chemother 57:6385-6388. http://dx.doi.org/10.1128/AAC.01604-13.
17. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 53:2733-2739. http://dx.doi.org/10.1128/AAC.00297-09.
18. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppe E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E. 2009. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 64:274-277. http://dx.doi.org/10.1093/jac/dkp194.
19. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. BMC Bioinformatics 10:421. http://dx.doi.org/10.1186/1471-2105-10-421.
20. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640-2644. http://dx.doi.org/10.1093/jac/dks261.
21. Oteo J, Perez-Vazquez M, Campos J. 2010. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 23:320-326. http://dx.doi.org/10.1097/QCO.0b013e3283398dc1.
22. Sidjabat HE, Paterson DL, Adams-Haduch JM, Ewan L, Pasculle AW, Muto CA, Tian GB, Doi Y. 2009. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother 53:4733-4739. http://dx.doi.org/10.1128/AAC.00533-09.
23. Zong Z, Yu R. 2010. Escherichia coli carrying the blaCTX-M-15 gene of ST648. J Med Microbiol 59:1536-1537. http://dx.doi.org/10.1099/jmm.0.022459-0.
24. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. 2012. Extended-spectrum beta-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 18:646-655. http://dx.doi.org/10.1111/j.1469-0691.2012.03850.x.
25. Mshana SE, Imirzalioglu C, Hain T, Domann E, Lyamuya EF, Chakraborty T. 2011. Multiple ST clonal complexes, with a predominance of ST131, of Escherichia coli harbouring blaCTX-M-15 in a tertiary hospital in Tanzania. Clin Microbiol Infect 17:1279-1282. http://dx.doi.org/10.1111/j.1469-0691.2011.03518.x.
26. Guenther S, Aschenbrenner K, Stamm I, Bethe A, Semmler T, Stubbe A, Stubbe M, Batsajkhan N, Glupczynski Y, Wieler LH, Ewers C. 2012. Comparable high rates of extended-spectrum-beta-lactamase-producing Escherichia coli in birds of prey from Germany and Mongolia. PLoS One 7:e53039. http://dx.doi.org/10.1371/journal.pone.0053039.
27. Guenther S, Ewers C, Wieler LH. 2011. Extended-spectrum beta-lactamase producing E. coli in wildlife, yet another form of environmental pollution? Front Microbiol 2:246. http://dx.doi.org/10.3389/fmicb.2011.00246.
28. Guenther S, Grobbel M, Beutlich J, Bethe A, Friedrich ND, Goedecke A, Lubke-Becker A, Guerra B, Wieler LH, Ewers C. 2010. CTX-M-15-type extended-spectrum beta-lactamases-producing Escherichia coli from wild birds in Germany. Environ Microbiol Rep 2:641-645. http://dx.doi.org/10.1111/j.1758-2229.2010.00148.x.
29. Cortes P, Blanc V, Mora A, Dahbi G, Blanco JE, Blanco M, Lopez C, Andreu A, Navarro F, Alonso MP, Bou G, Blanco J, Llagostera M. 2010. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl Environ Microbiol 76:2799-2805. http://dx.doi.org/10.1128/AEM.02421-09.
30. Ewers C, Bethe A, Stamm I, Grobbel M, Kopp PA, Guerra B, Stubbe M, Doi Y, Zong Z, Kola A, Schaufler K, Semmler T, Fruth A, Wieler LH, Guenther S. 2014. CTX-M-15-D-ST648 Escherichia coli from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence? J Antimicrob Chemother 69:1224-1230. http://dx.doi.org/10.1093/jac/dkt516.
31. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. 2013. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum betalactamase-producing Enterobacteriaceae. Int J Infect Dis 17:e159-163. http://dx.doi.org/10.1016/j.ijid.2012.09.010.
32. Lee CH, Su LH, Tang YF, Liu JW. 2006. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58:1074-1077. http://dx.doi.org/10.1093/jac/dkl381.